11 articles
Specific mutational signatures accumulate linearly with age in normal tissues, offering a new window into why cancer risk rises exponentially as we get older.
Fusobacterium nucleatum has shifted from suspected bystander to confirmed cancer driver — here's what the science reveals.
New review reveals how senescent cells both prevent and promote cancer, opening therapeutic opportunities.
A new perspective in Nature Cancer outlines how genetically engineered bacteria can target and destroy tumors from within.
New review reveals how advanced genomics tools are revolutionizing cancer diagnosis and therapy development.
A new review reveals how epithelial-to-mesenchymal transition fuels tumor invasion, immune evasion, and drug resistance through dynamic, reversible states.
A new review reframes how myeloid cells fuel or fight tumors, pointing to plasticity — not just cell diversity — as the core therapeutic target.
New research reveals how tumors might hijack sympathetic nervous system signals to boost their metabolism and proliferation.
A Dana-Farber review maps the path for personalized cancer vaccines — pinpointing which tumors, timing, and combination strategies will matter most.
New computational advances help identify which tumor peptides trigger immune responses, potentially revolutionizing personalized cancer therapy.
A Cochrane meta-analysis of 17 RCTs finds blue light TURBT reduces bladder cancer recurrence and progression, especially in intermediate- and high-risk patients.
